Search company, investor...
Search

Predict your next investment

Diversified Financial Services
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing / Accounting & Finance Services
nicengreen.ch

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

Partners & Customers

1

About Nice & Green

Nice & Green is a provider of corporate finance services. Its clients consist of small and medium companies that have reached a certain size and maturity and thus become eligible for access to the equity capital markets. It assists companies in finding solutions for their value enhancement or debt and equity financing via fully transparent process.

Nice & Green Headquarters Location

Chemin du Joran 10

Nyon, 1260,

Switzerland

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Nice & Green News

Amoeba : 15/09/22 - Amoéba announces the issuance of the sixth tranche of 60 bonds convertible into shares

Sep 15, 2022

06/13 06/13 09/15/2022 | 12:00pm EDT Message : PRESS RELEASE AMOEBA announces the issuance of the sixth tranche of 60 bonds convertible into shares as part of its new bond financing with incentive program with Nice & Green S.A. Chassieu (France), September 15, 2022- 5.45 pm - AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, still in a development phase, announces the issuance of the sixth tranche of bonds convertible into shares ("OCAs") of its new bond financing with incentive program, namely 60 OCAs numbered from 301 to 360 fully issued to Nice & Green S.A. This issue is part of the agreement entered into with Nice & Green S.A. on December 16, 2020 with a view to setting up a bond financing with a profit-sharing program through the issuance of 480 OCAs with a nominal value of EUR 50,000 each, representing a total nominal amount of the bond issue of EUR 24,000,000 (the "Issuance Agreement").1 The Chairman and Chief Executive Officer of the Company, using the sub-delegation granted to him by the Board of Directors at its meeting on June 24, 2021, decided to issue on September 15, 2022, 60 OCAs numbered from 301 to 360 to the benefit of Nice & Green S.A. corresponding to the sixth tranche of the bond financing. As provided for in the issuance agreement, these OCAs were fully subscribed at a price equal to 96% of their nominal value, representing a sixth tranche of OCAs for a total net amount of EUR 2,880,000. As a reminder, the Company maintains on its website a monitoring table of the OCAs and the number of Amoéba shares in circulation (see Investors section / Regulatories information / Other information). As an indication, the theoretical impact of the issue of this sixth tranche of OCAs is presented in the tables below in accordance with the OCA conversion formulas on the basis of 92% of the lowest volume-weighted average trading price of the Amoéba share at closing (as published by Bloomberg) over the six (6) trading days immediately preceding September 15, 2022, namely 0.9295 euros. Impact of the issue on the share of shareholders' equity per share (calculation based on Amoéba's shareholders' equity as at december 31, 2021, prepared in accordance with International Financial Reporting Standards (IFRS) adjusted for capital increases completed up to September 15, 2022 i. e. 11,445,684 euros and the number of shares comprising the Company's share capital as at September 15, 2022, i. e. 42,472,936 shares) : 1 See press release of December 21, 2020 Quote-part des capitaux propres au 31 décembre 2021 (en euros) * assuming: the full exercise of the business creator share subscription warrants and share subscription warrants issued and allocated by Amoéba, exercisable or not, giving the right to subscribe for 200,000 new shares the definitive allocation of the conditional rights to receive 25,000 free shares fully subject to a condition of uninterrupted presence. "The objectives of the financing programme with Nice & Green SA were to develop our biocontrol application worldwide on field crops, to continue the examination of our regulatory dossiers and to restructure the company's debt while strengthening its equity (see press release of 21 December 2020). To date, even before the end of the programme, I am pleased to note that these objectives have been achieved with, in particular, the implementation of 194 field trials between 2021 and 2022, the positive recommendation from Austria for the approval of our biocontrol active substance and the full early repayment of our loan from the EIB. Amoéba can now look forward to a new phase in its development and financing with the construction of a dedicated biocontrol plant and the search for new opportunities based on the use of the amoeba Willaertia Magna C2c Maky," said Fabrice Plasson, Chairman and CEO of Amoéba. About AMOEBA: Founded in 2010, Amoéba is a French company, based in Chassieu (Lyon, France), specialised in the treatment of microbiological risk in natural resources. Over the last ten years, Amoéba has developed a triple scientific, industrial and commercial expertise around the amoeba Willaertia magna C2c Maky. This biological solution is an alternative to the chemical products widely used today. Amoéba is currently focusing on the biocontrol market for plant protection, estimated at €1.6 billion (1), as well as on the US market for industrial water treatment in closed circuits. In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million (2) in the United States. The commercialisation of crop protection, biocides and healthcare products is subject to local regulatory approvals. The company is currently testing the biocontrol application for plant protection and does not market any products. Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. More information on www.amoeba-nature.com. 1. marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016. 2.Amoéba data

Nice & Green Investments

6 Investments

Nice & Green has made 6 investments. Their latest investment was in Evolva Holding as part of their PIPE - II on May 5, 2021.

CBI Logo

Nice & Green Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/17/2021

PIPE - II

Evolva Holding

No

1

1/27/2021

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

12/14/2020

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

5/20/2020

PIPE

Subscribe to see more

Subscribe to see more

10

9/18/2019

Option/Warrant

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/17/2021

1/27/2021

12/14/2020

5/20/2020

9/18/2019

Round

PIPE - II

Convertible Note

PIPE

PIPE

Option/Warrant

Company

Evolva Holding

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Nice & Green Portfolio Exits

1 Portfolio Exit

Nice & Green has 1 portfolio exit. Their latest portfolio exit was FacePhi on February 25, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/25/2020

IPO

$99M

Public

1

Date

2/25/2020

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

1

Nice & Green Partners & Customers

1 Partners and customers

Nice & Green has 1 strategic partners and customers. Nice & Green recently partnered with Saniona on December 12, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

12/29/2017

Partner

Denmark

Saniona AB: Saniona Establish Equity Financing of up to SEK 144 million

Saniona , a leading biotech company in the field of ion channels , announced today that it has entered into a convertible notes funding agreement with Nice Under the terms of the agreement , Nice has committed to subscribe up to SEK 72 million in convertible notes in individual tranches of SEK 6 million each over a 12-month period subject to prolongation by Saniona .

2

Date

12/29/2017

Type

Partner

Business Partner

Country

Denmark

News Snippet

Saniona AB: Saniona Establish Equity Financing of up to SEK 144 million

Saniona , a leading biotech company in the field of ion channels , announced today that it has entered into a convertible notes funding agreement with Nice Under the terms of the agreement , Nice has committed to subscribe up to SEK 72 million in convertible notes in individual tranches of SEK 6 million each over a 12-month period subject to prolongation by Saniona .

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.